Genetically Engineered Antitumor Monoclonal Antibodies

摘要: Antibodies have long been envisioned as potential clinical reagents. Although the development of hybridoma technology (Kohler and Milstein, 1975) has unleashed a vast array possibilities for generation monoclonal antibodies (MAbs) use in diagnosis therapy cancer other diseases, several limitations inherent to MAbs exist. For example, desired specificity may be difficult or even impossible generate using current methodology. Furthermore, MAb developed not affinity needed given function, MAb’s isotype optimal effector antibody-dependent cell-mediated cytotoxicity (ADCC).